A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

BACKGROUND: Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravis, Gwenaelle, Marino, Patricia, Olive, Daniel, Penault-LLorca, Frederique, Delord, Jean-Pierre, Simon, Clotilde, Lamrani-Ghaouti, Assia, Sabatier, Renaud, Ciccolini, Joseph, Boher, Jean-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155443/
https://www.ncbi.nlm.nih.gov/pubmed/37131154
http://dx.doi.org/10.1186/s12885-023-10881-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155443/
https://www.ncbi.nlm.nih.gov/pubmed/37131154
http://dx.doi.org/10.1186/s12885-023-10881-8

Ejemplares similares